Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma.

Related Articles

Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma.

J Thorac Oncol. 2018 Apr 24;:

Authors: Owen D, Chu B, Lehman AM, Annamalai L, Yearley JH, Shilo K, Otterson GA

Abstract
INTRODUCTION: Thymic epithelial tumors (TET) including thymoma and thymic carcinoma are rare tumors with little data available to guide treatment. Immunotherapy with checkpoint blockade has shown promising activity, but data regarding the expression patterns and prognostic implications of programmed death 1 (PD-1) and its ligand (PD-L1) in TET have yielded conflicting results. Intratumoral heterogeneity of PD-1/L1 expression has been demonstrated in other cancers but has not been described in the TET literature.
METHODS: We performed a retrospective single-center review of 35 patients with resected TET. PD-1/L1 expression was assessed by immunohistochemistry utilizing PD-1 clone: NAT105 and PD-L1 clone: 22C3. Tumor samples from 35 patients were evaluated including 32 patients with thymoma and 3 patients with thymic carcinoma.
RESULTS: PD-L1 expression was detected in 83% (29/35) tumor samples, including 100% (3/3) of thymic carcinoma patients and 81% (26/32) of thymoma patients. PD-1 expression was detected in 77% (27/35), including 33% (1/3) of thymic carcinoma patients and 81% (26/32) thymoma patients. High PD-1 expression was associated with lower grade tumors. Unlike prior studies, PD-L1 expression was not associated with higher grade tumors or higher stage. Neither PD-L1 nor PD-1 expression was significantly associated with survival. Three patients with thymoma had multiple tumor sections evaluated for expression of PD-1/L1, with differing expression patterns of both PD-L1 and PD-1 observed in two patients.
CONCLUSIONS: This study confirms high expression of PD-L1 and PD-1 in TET and demonstrates for the first time intra-tumoral heterogeneity of PD-L1 and PD-1 in thymoma patients.

PMID: 29702286 [PubMed - as supplied by publisher]

https://ift.tt/2HBrczQ